Xencor (NASDAQ:XNCR) VP Sells $27,572.04 in Stock

Xencor, Inc. (NASDAQ:XNCR) VP John Desjarlais sold 2,502 shares of the business’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $11.02, for a total transaction of $27,572.04. Following the transaction, the vice president directly owned 263,831 shares in the company, valued at approximately $2,907,417.62. The trade was a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Xencor Stock Up 4.9%

XNCR traded up $0.55 during trading hours on Monday, reaching $11.87. 835,908 shares of the stock traded hands, compared to its average volume of 711,120. The firm’s fifty day simple moving average is $12.79 and its two-hundred day simple moving average is $13.00. The company has a market cap of $870.55 million, a price-to-earnings ratio of -9.57 and a beta of 0.95. Xencor, Inc. has a fifty-two week low of $6.92 and a fifty-two week high of $18.69. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. The firm had revenue of $28.24 million for the quarter, compared to analyst estimates of $29.97 million. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The firm’s revenue was down 46.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.62) EPS. As a group, analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on XNCR. Barclays boosted their price target on Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Wall Street Zen downgraded Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Finally, Truist Financial initiated coverage on shares of Xencor in a research report on Monday, November 24th. They set a “buy” rating and a $29.00 price target for the company. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Institutional Trading of Xencor

Several institutional investors and hedge funds have recently bought and sold shares of XNCR. Walleye Capital LLC bought a new position in Xencor during the 2nd quarter worth approximately $1,955,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Xencor by 153.2% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 29,371 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 17,773 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Xencor by 3,150.0% during the 2nd quarter. Squarepoint Ops LLC now owns 363,153 shares of the biopharmaceutical company’s stock valued at $2,854,000 after acquiring an additional 351,979 shares in the last quarter. SG Americas Securities LLC bought a new position in Xencor during the third quarter worth $1,062,000. Finally, Panagora Asset Management Inc. lifted its stake in Xencor by 68.4% during the second quarter. Panagora Asset Management Inc. now owns 488,892 shares of the biopharmaceutical company’s stock worth $3,843,000 after purchasing an additional 198,564 shares during the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.